Dechra Pharmaceuticals (DPH) Stock Rating Reaffirmed by Jefferies Group

Jefferies Group reaffirmed their hold rating on shares of Dechra Pharmaceuticals (LON:DPH) in a report published on Wednesday morning. The brokerage currently has a GBX 2,221 ($30.12) target price on the stock.

Shares of Dechra Pharmaceuticals (DPH) opened at GBX 2,040 ($27.66) on Wednesday. Dechra Pharmaceuticals has a fifty-two week low of GBX 1,396 ($18.93) and a fifty-two week high of GBX 2,272 ($30.81). The stock has a market cap of $1,910.00 and a PE ratio of 7,285.71.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at

About Dechra Pharmaceuticals

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.

Analyst Recommendations for Dechra Pharmaceuticals (LON:DPH)

Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply